{
  "id": "63f03fc8f36125a426000021",
  "type": "factoid",
  "question": "What disease can be treated with Lenacapavir?",
  "ideal_answer": "Lenacapavir is a long-acting, highly potent HIV-1 capsid (CA) inhibitor that is approved for treatment of HIV-1.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/36272024",
    "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
    "http://www.ncbi.nlm.nih.gov/pubmed/36190128",
    "http://www.ncbi.nlm.nih.gov/pubmed/36202818"
  ],
  "snippets": [
    {
      "text": "Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36190128",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Lenacapavir (LEN) is a long-acting, highly potent HIV-1 capsid (CA) inhibitor. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36190128",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The investigational drug lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair HIV-1 inside the nucleus without displacing the tightly bound cellular cofactor from virus cores. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36202818",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lenacapavir (Sunlenca\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus type\u00a01 (HIV-1) being developed by Gilead Sciences Inc. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36272024",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In August 2022, lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen. This article summarizes the milestones in the development of lenacapavir leading to this first approval for the treatment of HIV-1 infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36272024",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lenacapavir: a first-in-class HIV-1 capsid inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE OF REVIEW: This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.RECENT FINDINGS: Lenacapavir demonstrated picomolar potency in vitro with no cross resistance to existing antiretroviral classes and potent antiviral activity in persons with HIV-1. In persons with HIV-1, there was no preexisting resistance to lenacapavir regardless of treatment history.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In heavily treatment-experienced persons with multidrug-resistant HIV-1 and in treatment-naive persons with HIV-1, lenacapavir in combination with other antiretroviral agents led to high rates of virologic suppression and was well tolerated.SUMMARY: Ongoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "HIV-1"
}